Investor Presentaiton

• Underlying trends are intact for continued growth Worldwide Drug R&D Spending ($ bn) WW Pharma R&D Spend ($bn) eurofins 20 220 200 +16% 213 207 202 +14% 180 196 189 160 179 182 +12% 168 +3.0% CAGR 2018-24 160 140 +10% 150 145 120 137 136 138 129 +6.7% +8% +6.2% +4.2% CAGR 2010-18 +6.5% 100 +6% +4.4% 80 60 +5.1% +3.7% +4% R&D Spend Growth (%) • +4.0% The Drug Discovery market is growing rapidly thanks to increasing R&D budgets, applicability of big data and artificial intelligence and cost optimisation requirements. It is estimated to grow at a CAGR of 14% between 2020 and 2025 to reach USD 21.4bn by 2025* In 2020 the FDA approved 53 novel drugs and 27 in H1 2021** The FDA has approved 29 biosimilars*** since 2015 +3.5% +3.2% 40 +2.8% +2.7% +2% О +16% 20 +0% • -0.4% 0 -2% Drug approvals fuel reinvestment across the R&D value chain Record cash on biotech balance sheets provides R&D funding through 2020 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Source: EvaluatePharma, May, 2019 Sponsors outsource drug development to: - Reduce their fixed cost base - Access competencies that they do not have in-house - Access experience and regulatory expertise in new geographies • R&D outsourcing rising rapidly: - In 2018 drug sponsors spent ca.$86bn on outsourced R&D services surpassing spend on internal staff and infrastructure by ca. $20bn, suggesting over 56% of R&D services are now outsourced by drug sponsors - According to the Tufts Center for the Study of Drug Development, study initiation cycle time is 77 days faster for CROS identifying and managing new investigative sites, compared to studies managed directly by drug sponsors - R&D pipelines continue to grow and a growing number of smaller pharma/biotech companies are entering the market Source: Tufts Center for the Study of Drug Development (Tufts CSDD), 5 Mar, 2019 * https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html?gclid=EAlalQobChMlq9j7kaOA8glVpCs4Ch1jmQK8EAAYASAAEgJ9QfD_BWE Note: this study includes markets and sub segments not served by Eurofins ** https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021-*** https://www.fda.gov/drugs/biosimilars/biosimilar-product-information 48

View entire presentation